Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BPN-36964
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tikun Gets FDA Orphan, Rare Pediatric Designation for Dysautonomia
Details : BPN-36964 is a gene replacement therapy and a small molecule splicing modulator, being investgated for systemic treatment of familial dysautonomia.
Product Name : BPN-36964
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 23, 2025
Lead Product(s) : BPN-36964
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable